Predictor | Model 1 | Model 2 | Model 3 | |||
---|---|---|---|---|---|---|
IRR (95% CI) | P | IRR (95% CI) | P | IRR (95% CI) | P | |
Baseline Slow Gait Speed | 3.18 (1.97–5.11) | < 0.001 | 3.27 (1.96–5.50) | < 0.001* | 3.09 (1.82–5.22) | < 0.001* |
Baseline ADAS-Cog | 0.95 (0.92–0.97) | 0.001* | 0.95 (0.92–0.98) | 0.001* | ||
Age | 1.07 (1.04–1.10) | < 0.001* | 1.07 (1.03–1.10) | < 0.001* | ||
Gender (Female) | 1.90 (1.15–3.11) | 0.012* | 1.60 (0.97–2.65) | 0.068 | ||
Study Arm | 1.20 (0.78–1.83) | 0.409 | 1.32 (0.85–2.06) | 0.218 | ||
Body Mass Index | 0.98 (0.94, 1.03) | 0.489 | 0.96 (0.92–1.01) | 0.149 | ||
Education (Years) | 1.07 (1.01–1.12) | 0.021* | 1.10 (1.04–1.15) | 0.001* | ||
Diagnosis Duration | 1.02 (0.88–1.17) | 0.816 | 0.96 (0.84–1.11) | 0.612 | ||
Total Comorbidities | 0.97 (0.88–1.07) | 0.527 | ||||
Diabetes Mellitus | 1.73 (0.85–3.51) | 0.128 | ||||
Arthritis | 2.19 (1.19–4.04) | 0.012* | ||||
Total Medications | 1.03 (0.95–1.12) | 0.490 | ||||
Benzodiazepine Use | 1.05 (1.04–3.64) | 0.036* | ||||
Antidepressant Use | 0.67 (0.41–1.07) | 0.096 |